OP Asset Management Ltd Makes New Investment in Pfizer Inc. $PFE

OP Asset Management Ltd purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,002,505 shares of the biopharmaceutical company’s stock, valued at approximately $28,150,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Horizon Financial Services LLC increased its stake in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Abound Financial LLC purchased a new position in Pfizer in the 4th quarter worth $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won FDA approval for an expanded IBRANCE regimen in metastatic breast cancer, a meaningful commercial and pipeline win for its oncology franchise.
• Positive Sentiment: The company advanced a pediatric pneumococcal “catch-up” vaccine into Phase 3, adding another potential growth catalyst to the pipeline.
• Positive Sentiment: Pfizer declared a $0.43 third-quarter dividend, extending its long streak of quarterly payouts and supporting the stock’s income profile.
• Neutral Sentiment: Pfizer reaffirmed its FY 2026 outlook despite leadership change chatter, which may help reassure investors but does not materially change the near-term growth story.
• Negative Sentiment: Sigvotatug vedotin missed its primary survival goal in Phase 3 lung cancer testing, renewing concerns about Pfizer’s oncology pipeline momentum and contributing to the stock’s weakness. Article Title

Pfizer Stock Down 2.7%

Shares of PFE stock opened at $24.05 on Thursday. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The stock has a market cap of $137.07 billion, a P/E ratio of 18.36 and a beta of 0.34. The stock has a 50 day moving average of $26.07 and a 200 day moving average of $26.31. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Wall Street Analyst Weigh In

Several research firms have weighed in on PFE. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. HSBC lifted their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Citigroup increased their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.